{"id":"W2744441485","doi":"10.1016/j.lungcan.2017.07.038","title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; Docetaxel; Refractory (planetary science); Population; Placebo; Lung cancer; Clinical endpoint; Surgery; Randomized controlled trial; Oncology; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001697122,0.001450018,0.002774657,0.0003640982,0.0004804293,0.00125005,0.0008727654,0.001175877,0.002641896],"category_scores_gemma":[0.001204448,0.0006255315,0.002953854,0.0003245054,0.001114395,0.001003465,0.0004166051,0.003783121,0.0005255438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001358545,"about_ca_system_score_gemma":0.001133658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00152751,"about_ca_topic_score_gemma":0.004549866,"domain_scores_codex":[0.9992232,0.0003935671,0.00003552187,0.0001279035,0.00005731476,0.0001625298],"domain_scores_gemma":[0.9991133,0.0002062183,0.0002425159,0.0000707076,0.00003558963,0.0003317519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948132,0.009455872,0.004018898,0.0003910401,0.001826269,0.00007493733,0.0001016213,0.000695223,0.00329813,0.0001102124,0.001079998,0.03081579],"study_design_scores_gemma":[0.8154802,0.1660805,0.01418662,0.00003882866,0.001622707,0.0001087227,0.00006379215,0.0006071497,0.0006372451,0.0001714342,0.0009681525,0.00003464854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945791,0.002969855,0.0001566644,0.0002963103,0.0001522624,0.000484754,0.0003927016,0.00003730674,0.000931092],"genre_scores_gemma":[0.9952822,0.001249401,0.000417347,0.0004814033,0.0002152895,0.0005198456,0.0006837897,0.0000156629,0.001135001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002774657,"threshold_uncertainty_score":0.009856939,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02050992220569165,"score_gpt":0.3717403769572913,"score_spread":0.3512304547515997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}